BioLineRx Ltd. Files 6-K for ADS Sale
Ticker: BLRX · Form: 6-K · Filed: Jan 6, 2025 · CIK: 1498403
Sentiment: neutral
Topics: capital-raise, stock-offering, filing
TL;DR
BioLineRx sold 5.6M+ ADSs on Jan 6, 2025. Raising capital.
AI Summary
On January 6, 2025, BioLineRx Ltd. announced the sale of 5,676,396 American Depositary Shares (ADSs), each representing fifteen ordinary shares. The company is based in Modi'in, Israel, and this filing is made under the 1934 Securities Exchange Act.
Why It Matters
This filing indicates a capital raise activity by BioLineRx Ltd., which could impact its financial resources and future development plans.
Risk Assessment
Risk Level: medium — The filing indicates a capital raise, which can be a positive sign of growth but also suggests potential dilution for existing shareholders.
Key Numbers
- 5,676,396 — ADSs Sold (Indicates capital raised through share offering.)
Key Players & Entities
- BioLineRx Ltd. (company) — Registrant
- January 6, 2025 (date) — Filing date and announcement date
- 5,676,396 (dollar_amount) — Number of American Depositary Shares sold
- Modi'in, Israel (location) — Company's principal executive offices
FAQ
What is the purpose of this Form 6-K filing?
The Form 6-K filing is to report a press release issued by BioLineRx Ltd. on January 6, 2025, concerning the sale of its American Depositary Shares.
How many American Depositary Shares did BioLineRx Ltd. sell?
BioLineRx Ltd. sold 5,676,396 of its American Depositary Shares.
What does each American Depositary Share represent?
Each American Depositary Share represents fifteen (15) ordinary shares of BioLineRx Ltd.
When was the press release regarding the ADS sale issued?
The press release was issued on January 6, 2025.
Where are BioLineRx Ltd.'s principal executive offices located?
BioLineRx Ltd.'s principal executive offices are located at 2 HaMa'ayan Street, Modi'in 7177871, Israel.
Filing Stats: 235 words · 1 min read · ~1 pages · Grade level 10.1 · Accepted 2025-01-06 08:55:06
Key Financial Figures
- $1.6 m — r total gross proceeds of approximately $1.6 million, through its "at-the-market" equi
Filing Documents
- zk2532512.htm (6-K) — 10KB
- exhibit_1.htm (EX-99.1) — 12KB
- 0001178913-25-000026.txt ( ) — 23KB
From the Filing
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission file number: 001-35223 BioLineRx Ltd. (Translation of registrant's name into English) 2 HaMa'ayan Street Modi'in 7177871, Israel (Address of Principal Executive Offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F Form 40-F On January 6, 2025, the Registrant issued the press release which is filed as Exhibit 1 to this Report on Form 6-K. During January 2025, the Registrant sold 5,676,396 of its American Depositary Shares, each representing fifteen (15) ordinary shares, par value NIS 0.10 per share, of the Registrant, for total gross proceeds of approximately $1.6 million, through its "at-the-market" equity offering program with H.C. Wainwright & Co., LLC, as sales agent. This Form 6-K and the press release attached to this Form 6-K as Exhibit 1 are hereby incorporated by reference into all effective registration statements filed by the registrant under the Securities Act of 1933. Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. BioLineRx Ltd. By: /s/ Philip A. Serlin Philip A. Serlin Chief Executive Officer Dated: January 6, 2025